Cited by 271Pharmacogenetics and Drug MetabolismComplementary and Alternative Medicine StudiesDrug Transport and Resistance Mechanisms

In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes

Open access
GURLEY, B, GARDNER, S, HUBBARD, M, WILLIAMS, D, GENTRY, W, KHAN, I, SHAH, A·2005·Clinical Pharmacology & Therapeutics

Abstract

OBJECTIVES: Phytochemical-mediated modulation of cytochrome P450 (CYP) activity may underlie many herb-drug interactions. Single-time point phenotypic metabolic ratios were used to determine whether long-term supplementation of goldenseal ( Hydrastis canadensis ), black cohosh ( Cimicifuga racemosa ), kava kava ( Piper methysticum ), or valerian ( Valeriana officinalis ) extracts affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4/5 activity. METHODS: Twelve healthy volunteers (6 women) were randomly assigned to receive goldenseal, black cohosh, kava kava, or valerian for 28 days. For each subject, a 30-day washout period was interposed between each supplementation phase. Probe drug cocktails of midazolam and caffeine, followed 24 hours later by chlorzoxazone and debrisoquin (INN, debrisoquine), were administered before (baseline) and at the end of supplementation. Presupplementation and postsupplementation phenotypic trait measurements were determined for CYP3A4/5, CYP1A2, CYP2E1, and CYP2D6 by use of 1-hydroxymidazolam/midazolam serum ratios (1-hour sample), paraxanthine/caffeine serum ratios (6-hour sample), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour sample), and debrisoquin urinary recovery ratios (8-hour collection), respectively. The content of purported "active" phytochemicals was determined for each supplement. RESULTS: Comparisons of presupplementation and postsupplementation phenotypic ratio means revealed significant inhibition (approximately 40%) of CYP2D6 (difference, -0.228; 95% confidence interval [CI], -0.268 to -0.188) and CYP3A4/5 (difference, -1.501; 95% CI, -1.840 to -1.163) activity for goldenseal. Kava produced significant reductions (approximately 40%) in CYP2E1 only (difference, -0.192; 95% CI, -0.325 to -0.060). Black cohosh also exhibited statistically significant inhibition of CYP2D6 (difference, -0.046; 95% CI, -0.085 to -0.007), but the magnitude of the effect (approximately 7%) did not appear to be clinically relevant. No significant changes in phenotypic ratios were observed for valerian. CONCLUSIONS: Botanical supplements containing goldenseal strongly inhibited CYP2D6 and CYP3A4/5 activity in vivo, whereas kava inhibited CYP2E1 and black cohosh weakly inhibited CYP2D6. Accordingly, serious adverse interactions may result from the concomitant ingestion of goldenseal supplements and drugs that are CYP2D6 and CYP3A4/5 substrates. Kava kava and black cohosh may interact with CYP2E1 and CYP2D6 substrates, respectively. Valerian appears to be less likely to produce CYP-mediated herb-drug interactions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clpt.2005.01.009

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Goldenseal supplementation markedly inhibited the metabolism of midazolam, a CYP3A probe substrate, with an increase in exposure on the order of 40-60%.

    “Goldenseal supplementation markedly inhibited the metabolism of midazolam, a CYP3A probe substrate, with an increase in exposure on the order of 40–60% [72,73].”

    From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [72]

    The Methods identify midazolam as the CYP3A4/5 probe, and the Results report approximately 40% inhibition of CYP3A4/5 activity after goldenseal supplementation. But that figure describes a change in a single-time-point metabolic ratio, not a measured 40–60% increase in midazolam exposure; the Introduction distinguishes this method from area-under-the-curve exposure measurements. No page numbers are available in our copy. (LLM, conf=0.90)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 6

  1. [4]Gurley BJ, Hagan DW. Herbal and dietary supplement interactions with drugs. In: McCabe BJ, Frankel EH, Wolfe JJ, editors. Handbook of Food-Drug Interactions. Boca Raton: CRC Press; 2003. pp. 259–293. [Google Scholar]
  2. [46]Ganzera M, Bedir E, Khan IA. Separation of Cimicifuga racemosa triterpene glycosides by evaporative light scattering detection. Chromatographia. 2000;52:301–304. [Google Scholar]
  3. [48]The Pharmacopeia of the United States Twenty-seventh Revision, and the National Formulary. 22. Rockville: United States Pharmacopeial Convention, Inc.; 2004. Disintegration and dissolution of dietary supplements; pp. 2645–2646. [Google Scholar]
  4. [49]Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2. Lawrence Erlbaum Associates Publishers; 1988. pp. 19–42. [Google Scholar]
  5. [50]Chatterjee P, Franklin MR. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003;31:1391–1397. doi: 10.1124/dmd.31.11.1391. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  6. [61]Food and Drug Administration. Letter to health-care professionals: FDA issues consumer advisory that kava products may be associated with severe liver injury. Vol. 36. US Department of Health and Human Services; Rockville, MD: May/June, 2002. p. 4. Available at http://www.cfsan.fda.gov/~dms/addskava.html. [Google Scholar]

Cited by

Sorted by citations

Authors
GURLEY, B., GARDNER, S., HUBBARD, M., WILLIAMS, D., GENTRY, W., KHAN, I., & SHAH, A.
Affiliations
University of Mississippi (US)
Corresponding author
GURLEY, B
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2005-05
Volume
77
Issue
5
Pages
415-426
ISSN
0009-9236 (ISSN-L)
OpenAlex
W1966006812
Cited by
271
References
58
Citations by year
2026: 7 · 2025: 9 · 2024: 8 · 2023: 5 · 2022: 12 · 2021: 12 · 2020: 16 · 2019: 10 · 2018: 12 · 2017: 4 · 2016: 7 · 2015: 15 · 2014: 15 · 2013: 15 · 2012: 20
FWCI
15.25
Type
journal article
Language
en
Open access
Locations
  • Clinical Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of General Medical Sciences (R01GM071322, GM71322-01A2)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
goldenseal, Hydrastis canadensis, kava, black cohosh, Cimicifuga racemosa, Valeriana officinalis, cytochrome P450, herb-drug interactions, CYP2D6 inhibition, CYP2E1, CYP1A2, phytochemicals, herbal supplements, midazolam hydroxylation
MeSH terms
Adult, Aryl Hydrocarbon Hydroxylases, Caffeine, Capsules, Drug Administration Schedule, Female, Humans, Male, Midazolam, Phenotype, Time Factors, Valerian, Patient Selection, Dietary Supplements, Kava, Cimicifuga, Hydrastis, Herb-Drug Interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review